# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The highlights of presentation are as follows: The primary endpoints were safety and tolerability of MN-166 and TMZ combinatio...
Abstract Number: 2106 Title: Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients ...
Shares of MariaDB plc (NYSE: MRDB) rose sharply in today’s pre-market trading after Progress Software (NASDAQ: PRGS) announce...
Once issued, this patent is expected to expire no earlier than October 2039. The allowed claims cover the use of MN-166 (ibudi...